News
04-07-2019, 10:12 PM
On April 8, Celltrion and the Canada-based iProgen Biotech Inc. announced to agree to partner for the development of novel ADCs against validated antibody targets, including HER2 and CD20.
More... (https://www.news-medical.net/news/20190408/Celltrion-and-iProgen-Biotech-announce-partnership-for-development-of-novel-ADCs.aspx)
More... (https://www.news-medical.net/news/20190408/Celltrion-and-iProgen-Biotech-announce-partnership-for-development-of-novel-ADCs.aspx)